Downloadable tables: Antimicrobial consumption - Annual Epidemiological Report for 2015
Data from the Antimicrobial consumption - Annual Epidemiological Report for 2015
Download
Available tables
Table D1. Trends in consumption of tetracyclines (ATC group J01A) in the community, EU/EEA, 2011–2015, expressed as DDD per 1 000 inhabitants per day
Table D2. Trends in consumption of beta-lactams, penicillins (ATC group J01C) in the community, EU/EEA, 2011–2015, expressed as DDD per 1 000 inhabitants per day
Table D3. Trends in consumption of other beta-lactams (ATC group J01D) in the community, EU/EEA, 2011–2015, expressed as DDD per 1 000 inhabitants per day
Table D4. Trends in consumption of sulfonamides and trimethoprim (ATC group J01E) in the community, EU/EEA, 2011–2015, expressed as DDD per 1 000 inhabitants per day
Table D5. Trends in consumption of macrolides, lincosamides and streptogramins (ATC group J01F) in the community, EU/EEA, 2011–2015, expressed as DDD per 1 000 inhabitants per day
Table D6. Trends in consumption of quinolone antibacterials (ATC group J01M) in the community, EU/EEA, 2011–2015, expressed as DDD per 1 000 inhabitants per day
Table D7. Trends in consumption of other antibacterials (ATC group J01X) in the community, EU/EEA, 2011–2015, expressed as DDD per 1 000 inhabitants per day
Table D8. Consumption of antibacterials for systemic use (ATC group J01) by ATC group level 3 in the community, EU/EEA, 2015, expressed as packages per 1 000 inhabitants per day
Table D9. Trends in consumption of antibacterials for systemic use in the community, EU/EEA, 2011–2015, expressed as packages per 1 000 inhabitants per day
Table D10. ESAC quality indicators for consumption data of antibacterials for systemic use (ATC group J01), for the community, EU/EEA, 2015
Table D11. Consumption of oral vancomycin (A07AA09), rifampicin (J04AB02) and oral and rectal metronidazole (P01AB01) in the community, EU/EEA, 2015, expressed as DDD per 1 000 inhabitants per day
Table D12. Trends in consumption of carbapenems (ATC group J01DH) in the hospital sector, EU/EEA, 2011–2015, expressed as DDD per 1 000 inhabitants per day
Table D13. Trends in consumption of polymyxins (ATC group J01XB) in the hospital sector, EU/EEA, 2011–2015, expressed as DDD per 1 000 inhabitants per day
Table D14. Consumption of oral vancomycin (A07AA09), rifampicin (J04AB02) and oral and rectal metronidazole (P01AB01) in the hospital sector, EU/EEA, 2015, expressed as DDD per 1 000 inhabitants per day
Table D15. Consumption of antimycotics (ATC group J02) and antifungals (ATC group D01B) for systemic use in the community, EU/EEA, 2015, expressed as DDD per 1 000 inhabitants per day
Table D16. Consumption of antimycotics (ATC group J02) and antifungals (ATC group D01B) for systemic use in the hospital sector, EU/EEA, 2015, expressed as DDD per 1 000 inhabitants per day
Table D17. Consumption of antivirals (ATC group J05) for systemic use in both sectors (community and hospital sector), EU/EEA, 2015, expressed as DDD per 1 000 inhabitants per day
Table D18. Consumption of antivirals (ATC group J05) for systemic use in both sectors (community and hospital sector), grouped into categories of their main indication, EU/EEA, 2015, expressed as DDD per 1 000 inhabitants per day